Navigation Links
Cempra, Inc. Announces Pricing of Its Initial Public Offering of Common Stock
Date:2/3/2012

CHAPEL HILL, N.C., Feb. 3, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the pricing of its initial public offering of 8,400,000 shares of its common stock at a price to the public of $6.00 per share.  Cempra also has granted the underwriters a 30-day option to purchase up to an additional 1,260,000 shares to cover over-allotments, if any.

Shares of Cempra's common stock will trade on the NASDAQ Global Market under the symbol "CEMP" beginning on February 3, 2012. The closing of the offering is expected to occur on February 8, 2012, subject to the satisfaction of customary closing conditions. 

Stifel Nicolaus Weisel, Leerink Swann LLC and Cowen and Company, LLC are serving as joint book-running managers for the offering.  Needham & Company, LLC is acting as co-manager.

The offering of these securities will be made only by means of a prospectus.  A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission.  This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state. 

A copy of the prospectus relating to the offering may be obtained by contacting Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720; Leerink Swann LLC, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by calling (800) 808-7525; or Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, or by calling (631) 274-2806.  The final prospectus, when it is available, also may be obtained on the Securities and Exchange Commission's Web site at www.sec.gov.

About Cempra

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Contact:

Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
robert.flamm@russopartnersllc.com

Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251
Tony.russo@russopartnersllc.com

Dr. Prabhavathi Fernandes
President and Chief Executive Officer
(919) 467-1716
pfernandes@cempra.com


'/>"/>
SOURCE Cempra, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2011 Earnings Conference Call Webcast
2. Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184
3. CryoLife Announces Release Date and Teleconference Call Details for 2011 Fourth Quarter and Year End Financial Results
4. Perrigo Company Announces Quarterly Dividend
5. BioParadox Announces Partnership with Fogarty Institute for Innovation
6. Hybrid Fuels, Inc. Announces FDA Approved Lab Selection for Azul Instant™ - "Be Ready in an Instant"
7. Nautilus Neurosciences Announces New Patent Issued
8. Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe
9. Sapio Sciences Announces Exemplar Dx LIMS for Laboratories in the Burgeoning MDx Market
10. Medical Alarm to Begin Fulfillment of MediPendant™ Against Largest Purchase Order - Announces Additional Warrant Cancellations
11. RemedyMD Announces Investigate Cell Therapy, a Revolutionary Research Management System for Blood and Marrow Transplant Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... YORK , Jan. 17, 2017 Immune ... stage biopharmaceutical company, announced today that it will hold ... Symposium on Acute Leukemias (ISAL) XVI in ... is entitled:  "Reinforcing the Efficacy of Immunotherapy for the ... take place on Monday February 20 th , 2017 from ...
(Date:1/17/2017)... Jan. 17, 2017 Interpace Diagnostics Group, Inc., (NASDAQ: ... molecular diagnostic tests and pathology services for evaluating risks ... letter dated January 13, 2017 from the NASDAQ Listing ... with the requirement of the NASDAQ Stock Market to ... share. The letter noted that for the ...
(Date:1/17/2017)... -- Research and Markets has announced the addition of the ... offering. ... comprehensive report, identifies and profiles the leading 200 manufacturers and distributors of ... the United States and Europe ... . Profile information for each company in The Top ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... ... California Southern University has named Dr. Steven Beazley University President. ... a core faculty member, teaching master’s and doctoral courses in the university’s School of ... where he earned his Doctor of Psychology degree in 1998. Dr. Beazley also has ...
(Date:1/16/2017)... ... January 16, 2017 , ... With the Grand Opening Event planned for February ... by sports teams and the general public. Built in five months by Centerpoint, the ... converted into basketball or pickleball courts. The space is also suitable for indoor soccer ...
(Date:1/16/2017)... ... January 16, 2017 , ... As New York’s fastest ... Giamos, MD to their medical staff, according to eye surgeon, Jeffrey Martin, MD, ... Care, a division of SightMD. Dr. Giamos will practice primarily out of SightMD’s ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... their recent partnership with an innovator in the wheelchair accessibility industry, BraunAbility ... their dealer salespeople to sell wheelchair accessible vehicles. With this new incentive plan, ...
(Date:1/16/2017)... Hills, CA (PRWEB) , ... January 16, 2017 ... ... a manuscript in the Aesthetic Surgery Journal , the official journal of ... he conducted on lower eyelid retraction surgery. The procedure is designed to correct ...
Breaking Medicine News(10 mins):